Eptifibatide Evidence Guide
Eptifibatide (Integrilin) is FDA-approved for acute coronary syndrome and PCI with Phase 3 evidence from the PURSUIT and ESPRIT trials demonstrating reduced composite ischemic endpoints. As a cyclic RGD peptide GP IIb/IIIa inhibitor, it provides potent antiplatelet effect during percutaneous intervention. A well-established cardiovascular drug with a clear, validated indication.
Our Take
Eptifibatide (Integrilin) is FDA-approved for acute coronary syndrome and PCI with Phase 3 evidence from the PURSUIT and ESPRIT trials demonstrating reduced composite ischemic endpoints. As a cyclic RGD peptide GP IIb/IIIa inhibitor, it provides potent antiplatelet effect during percutaneous intervention. A well-established cardiovascular drug with a clear, validated indication.
- Evidence context
- Acute coronary syndrome management, PCI antiplatelet therapy, GP IIb/IIIa inhibition research
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 180mcg/kg IV bolus then 2mcg/kg/min infusion for 18-24 hours (ACS/PCI dosing)
Benefits and Evidence
- Acute Coronary Syndrome: Level A, includes human evidence - PURSUIT trial (10,948 patients) showed significant reduction in death or myocardial infarction at 30 days when added to standard therapy in unstable angina/NSTEMI.
- PCI Outcomes: Level A, includes human evidence - ESPRIT trial demonstrated significant reduction in ischemic events when used during percutaneous coronary intervention with stenting.
- Bleeding Risk: Level A, includes human evidence - Increased risk of bleeding complications, particularly at vascular access sites. Major bleeding rates approximately 1-3% higher than placebo in clinical trials.
Side Effects and Warnings
- Bleeding (major and minor)
- Thrombocytopenia
- Hypotension
- Back pain
- Nausea
- Contraindicated with active internal bleeding or recent surgery
- Severe thrombocytopenia (<100,000/mm3) - discontinue immediately
- Renal dose adjustment required (CrCl <50 mL/min)
Research Dosage References
- <strong>Intravenous bolus + infusion</strong> - 180 mcg/kg bolus, then 2 mcg/kg/min - Continuous infusion for up to 72 hours (ACS) or 18-24 hours post-PCI - For PCI: double bolus (180 mcg/kg at time 0, repeat at 10 min). Reduce infusion to 1 mcg/kg/min if CrCl <50 mL/min.
Mechanism of Action
Eptifibatide prevents platelet aggregation through glycoprotein receptor blockade: 1. GP IIb/IIIa receptor antagonism: Reversibly binds to the glycoprotein IIb/IIIa receptor on activated platelets, preventing fibrinogen and von Willebrand factor cross-linking. 2. KGD mimicry: The Lys-Gly-Asp sequence mimics the binding domain of fibrinogen, competitively blocking the final common pathway of platelet aggregation. 3. Rapid onset and offset: Short half-life allows rapid restoration of platelet function after discontinuation, providing a controllable antiplatelet effect.
Legal Status
FDA-approved for acute coronary syndrome and percutaneous coronary intervention. Available by prescription for hospital use only. Marketed as Integrilin by Merck.
Primary Sources
- Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes (PURSUIT). N Engl J Med, 1998.
- Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT). Lancet, 2000.
- Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing PCI. Drugs, 2005.
Quick Answers
Where is the strongest evidence for Eptifibatide?
Eptifibatide (Integrilin) is FDA-approved for acute coronary syndrome and PCI with Phase 3 evidence from the PURSUIT and ESPRIT trials demonstrating reduced composite ischemic endpoints. As a cyclic RGD peptide GP IIb/IIIa inhibitor, it provides potent antiplatelet effect during percutaneous intervention. A well-established cardiovascular drug with a clear, validated indication. Evidence context: Acute coronary syndrome management, PCI antiplatelet therapy, GP IIb/IIIa inhibition research.
What are the main side effects of Eptifibatide?
Eptifibatide side effects and warning signals include Bleeding (major and minor), Thrombocytopenia, Hypotension, Back pain, and Nausea.
What evidence level is Eptifibatide?
Eptifibatide is rated Level A; the listed research status is FDA Approved.